Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Dec;49(11):1014-6.
doi: 10.1310/hpj4911-1014.

Rifaximin: irritable bowel syndrome

Joyce A Generali  1 , Dennis J Cada  2
Affiliations

Rifaximin: irritable bowel syndrome

Joyce A Generali et al. Hosp Pharm. 2014 Dec.

Abstract

This Hospital Pharmacy feature is extracted from Off-Label Drug Facts, a publication available from Wolters Kluwer Health. Off-Label Drug Facts is a practitioner-oriented resource for information about specific drug uses that are unapproved by the US Food and Drug Administration. This new guide to the literature enables the health care professional or clinician to quickly identify published studies on off-label uses and determine if a specific use is rational in a patient care scenario. References direct the reader to the full literature for more comprehensive information before patient care decisions are made. Direct questions or comments regarding Off-Label Drug Uses to jgeneral@ku.edu.

PubMed Disclaimer

Similar articles

See all similar articles

References

    1. Ford AC, Moayyedi P, Lacy BE, et al. American College of Gastroenterology monograph on the management of irritable bowel syndrome and chronic idiopathic constipation. Am J Gastroenterol. 2014;109(Suppl 1):S2–S26. - PubMed
    1. Saadi M, McCallum RW.Rifaximin in irritable bowel syndrome: Rationale, evidence and clinical use. Ther Adv Chronic Dis. 2013;4(2):71–75. - PMC - PubMed
    1. Saha L.Irritable bowel syndrome: Pathogenesis, diagnosis, treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(22):6759–6773. - PMC - PubMed
    1. Wall GC, Bryant GA, Bottenberg MM, Maki ED, Miesner AR.Irritable bowel syndrome: A concise review of current treatment concepts. World J Gastroenterol. 2014;20(27):8796–8806. - PMC - PubMed
    1. Pimentel M, Lembo A, Chey WD, et al.; TARGET Study Group. Rifaximin therapy for patients with irritable bowel syndrome without constipation. N Engl J Med. 2011;364(1):22–32. - PubMed

LinkOut - more resources